Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other
Ratios

Adlai Nortye (ANL) Receivables - Other (2023 - 2025)

Adlai Nortye (ANL) reported Receivables - Other of $907000.0 for Q4 2025, up 262.8% year-over-year from $250000.0 in Q4 2024, and up 262.8% on a QoQ basis from $250000.0 in Q4 2024.

Adlai Nortye (ANL) has 3 years of Receivables - Other data on file, last reported at $907000.0 in Q4 2025.

  • Quarterly Receivables - Other rose 262.8% year-over-year to $907000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $907000.0 (up 262.8% YoY) and the FY2025 annual result came in at $907000.0, up 262.8% from the prior year.
  • Receivables - Other advanced to $907000.0 in Q4 2025 per ANL's latest filing, from $250000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $907000.0 in Q4 2025 and bottomed at $224000.0 in Q4 2023.
  • The 3-year median for Receivables - Other is $250000.0 (2024), against an average of $460333.3.
  • The widest annual swing landed in 2024, when Receivables - Other rose 11.61%; it then soared 262.8% in 2025.
  • Tracing ANL's Receivables - Other over 3 years: stood at $224000.0 in 2023, then advanced by 11.61% to $250000.0 in 2024, then soared by 262.8% to $907000.0 in 2025.
  • Per Business Quant, the three latest ANL Receivables - Other figures stand at $907000.0 (Q4 2025), $250000.0 (Q4 2024), and $224000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Adlai Nortye 23,840.00 -8.03 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 907,000.00
Dec 31, 2025 907,000.00
Dec 31, 2024 250,000.00
Dec 31, 2024 250,000.00
Dec 31, 2023 224,000.00
Dec 31, 2023 224,000.00